Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, explains the Oncotype DX® Breast Cancer Assay and how it is performed, detailing the specificities of the test and how the Recurrence Score® result is reported.
She highlights how her multidisciplinary team chooses to use a genomic test, such as the Oncotype DX assay, to guide adjuvant chemotherapy decisions in luminal breast cancers.
She comments on the use of the Oncotype DX assay with traditional markers and other markers such as ER, PR or HER2. The Recurrence Score result is complementary for select patients.
Her conclusion is that the information from the Oncotype DX assay supports patient discussions.
This content is supported by Genomic Health, Inc.
